Literature DB >> 2948825

Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease.

R A Roos, E J de Haas, O J Buruma, F A de Wolff.   

Abstract

The pharmacokinetics of tiapride were determined at steady-state in 5 patients with tardive dyskinesia and 2 patients with Huntington's disease given tiapride 100 mg t.i.d. for 7 days. The maximum serum concentration of tiapride of 1.47 +/- 0.35 micrograms/ml was reached after 1.4 +/- 0.67 h. The half-life time of elimination was 229 +/- 41 min. About 50% of the dose of tiapride was excreted unchanged by the kidney. Neither protein binding nor glucuronide, sulphate or acetyl conjugation was observed. Renal clearance in the patients appeared to be lower but the other pharmacokinetic parameters did not differ from previous findings in healthy young volunteers.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2948825     DOI： 10.1007/bf00606657

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  11 in total

1.  [Absorption, elimination and metabolism of a new neuroleptic agent (FLO 1347) in the rat dog and man (author's transl)].

Authors:  M Strolin-Benedetti; A Donath; A Frigerio; K T Morgan; C Laville; A Malnoe
Journal:  Ann Pharm Fr       Date:  1978

2.  Tiapride in levodopa-induced involuntary movements.

Authors:  B Mejer Nielsen
Journal:  Acta Neurol Scand       Date:  1983-06       Impact factor: 3.209

3.  [A clinical trial of tiapride in neurology (author's transl)].

Authors:  A Lipcsey; E Nagy
Journal:  Sem Hop       Date:  1982-04-08

4.  Tiapride in the treatment of Huntington's chorea.

Authors:  R A Roos; O J Buruma; G W Bruyn; B Kemp; E A van der Velde
Journal:  Acta Neurol Scand       Date:  1982-01       Impact factor: 3.209

5.  Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms.

Authors:  E Rey; P d'Athis; M O Richard; D de Lauture; G Olive
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-02

6.  Tiapride in levodopa-induced involuntary movements.

Authors:  A J Lees; C M Lander; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-04       Impact factor: 10.154

7.  Tiapride in the treatment of tardive dyskinesia.

Authors:  O J Buruma; R A Roos; G W Bruyn; B Kemp; E A van der Velde
Journal:  Acta Neurol Scand       Date:  1982-01       Impact factor: 3.209

8.  [Clinical trial of tiapride in patients with dyskinesia (author's transl)].

Authors:  C Chouza; S Romero; J Lorenzo; J L Camano; A P Fontana; P Alterwain; D Cibils; J Gaudiano; S Feres; J Solana
Journal:  Sem Hop       Date:  1982-03-25

9.  Effects of tiapride in tardive dyskinesia.

Authors:  P Pollak; J M Gaio; M Hommel; J Pellat; J Perret
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  [Tiapride in the treatment of neurological and psychiatric disorders in the elderly (author's transl)].

Authors:  G Miletto; M Julou
Journal:  Sem Hop       Date:  1981 Nov 18-25
View more
  6 in total

1.  Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.

Authors:  Melissa J Armstrong; Janis M Miyasaki
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

2.  Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease.

Authors:  T Norman; E Chiu; R H James; M S Gregory
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  The Many Faces of Huntington's Chorea Treatment: The Impact of Sudden Withdrawal of Tiapride after 40 Years of Use and a Systematic Review.

Authors:  Stephanie Feleus; Malu van Schaijk; Raymund A C Roos; Susanne T de Bot
Journal:  J Pers Med       Date:  2022-04-06

4.  A new oral formulation of tiapride (drops): pharmacokinetic profile and therapeutic applications.

Authors:  M Canal; C R Desanti; J P Santoni
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 5.  Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation.

Authors:  J W Steele; D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 6.  Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.

Authors:  D H Peters; D Faulds
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.